BioCryst Pharmaceuticals ...

8.39
0.17 (2.07%)
At close: Apr 25, 2025, 3:59 PM
8.40
0.06%
After-hours: Apr 25, 2025, 05:49 PM EDT

BioCryst Pharmaceuticals Statistics

Share Statistics

BioCryst Pharmaceuticals has 208.96M shares outstanding. The number of shares has increased by 1.25% in one year.

Shares Outstanding 208.96M
Shares Change (YoY) 1.25%
Shares Change (QoQ) 0.88%
Owned by Institutions (%) 81.03%
Shares Floating 197.24M
Failed to Deliver (FTD) Shares 37.05K
FTD / Avg. Volume 1.04%

Short Selling Information

The latest short interest is 20.73M, so 9.92% of the outstanding shares have been sold short.

Short Interest 20.73M
Short % of Shares Out 9.92%
Short % of Float 10%
Short Ratio (days to cover) 7.27

Valuation Ratios

The PE ratio is -17.49 and the forward PE ratio is 35.74. BioCryst Pharmaceuticals's PEG ratio is 0.28.

PE Ratio -17.49
Forward PE 35.74
PS Ratio 3.45
Forward PS 1.9
PB Ratio -3.27
P/FCF Ratio -29.88
PEG Ratio 0.28
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for BioCryst Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.63, with a Debt / Equity ratio of -0.03.

Current Ratio 2.63
Quick Ratio 2.58
Debt / Equity -0.03
Debt / EBITDA 1
Debt / FCF -0.25
Interest Coverage -0.03

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $777.09K
Profits Per Employee $-153.24K
Employee Count 580
Asset Turnover 0.92
Inventory Turnover 1.52

Taxes

Income Tax 1.93M
Effective Tax Rate -2.22%

Stock Price Statistics

The stock price has increased by 101.68% in the last 52 weeks. The beta is 1.75, so BioCryst Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.75
52-Week Price Change 101.68%
50-Day Moving Average 7.85
200-Day Moving Average 7.74
Relative Strength Index (RSI) 64.65
Average Volume (20 Days) 3.56M

Income Statement

In the last 12 months, BioCryst Pharmaceuticals had revenue of 450.71M and earned -88.88M in profits. Earnings per share was -0.43.

Revenue 450.71M
Gross Profit 438.44M
Operating Income -2.54M
Net Income -88.88M
EBITDA 12.81M
EBIT 11.56M
Earnings Per Share (EPS) -0.43
Full Income Statement

Balance Sheet

The company has 104.71M in cash and 12.82M in debt, giving a net cash position of 91.89M.

Cash & Cash Equivalents 104.71M
Total Debt 12.82M
Net Cash 91.89M
Retained Earnings -1.77B
Total Assets 490.42M
Working Capital 261.58M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -52.02M and capital expenditures 0, giving a free cash flow of -52.02M.

Operating Cash Flow -52.02M
Capital Expenditures 0
Free Cash Flow -52.02M
FCF Per Share -0.25
Full Cash Flow Statement

Margins

Gross margin is 97.28%, with operating and profit margins of -0.56% and -19.72%.

Gross Margin 97.28%
Operating Margin -0.56%
Pretax Margin -19.29%
Profit Margin -19.72%
EBITDA Margin 2.84%
EBIT Margin -0.56%
FCF Margin -11.54%

Dividends & Yields

BCRX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for BCRX is $13.5, which is 60.9% higher than the current price. The consensus rating is "Buy".

Price Target $13.5
Price Target Difference 60.9%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score -2.37
Piotroski F-Score 3